Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$4.77 USD
+0.13 (2.80%)
Updated May 31, 2024 04:00 PM ET
After-Market: $4.87 +0.10 (2.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 61 - 80 ( 162 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Reports Favorable Preliminary Safety Across Its Three Annamycin Trials
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Interim Third Dose Cohort Data Released- Single Agent Annamycin in STSLM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Mix and GMs Drive Upside; Raising Estimates and PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Full Clinical Trial Plate, Solid Annamycin Data, Well-Funded to 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Highly Encouraging Interim Phase 1b Annamycin Results in STS-LM Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
STS/LM Trial Cohort 1 Dose Shows Highly Favorable Safety Profile
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Expanding Clinical Pipeline, Well-Funded at Least Through 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Allowed to Extend Dose Escalation in E.U. Phase 1/2 Annamycin AML Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Expanding Clinical Pipeline, Well-Funded at Least Through 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Gets 4th Rare Pediatric Disease Designation for WP1066, 4 Potential PRVs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J